Skip to content

A Study on the Clinical Efficacy and Underlying Mechanism of Zeling Guanjie Xiaozhong Mixture in the Treatment of Knee Osteoarthritis

A Study on the Clinical Efficacy and Underlying Mechanism of Zeling Guanjie Xiaozhong Mixture in the Treatment of Knee Osteoarthritis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000829
Enrollment
Unknown
Registered
2024-12-15
Start date
2024-05-20
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Experimental group:Oral celecoxib capsule and Zeling Guanjie Xiaozhong Mixture

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for knee osteoarthritis (KOA) according to Western medicine with a traditional Chinese medicine syndrome type of damp-heat obstruction syndrome; 2. Radiographic grading between Grade I and Grade III; 3. Age between 50 and 75 years inclusive with no gender restriction; 4. Understands and agrees to participate in this study and has signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with complications such as gout or rheumatoid arthritis affecting the joints; 2. X-ray findings indicating extensive osteophyte formation significant narrowing or disappearance of joint space or joint deformities; 3. Patients with valgus or varus deformity of the knee joint lower limb disability or in the advanced stage of the disease with loss of working ability; 4. Patients with disease caused by trauma or who have undergone local knee joint surgery; 5. Use of other types of anti-inflammatory analgesics or corticosteroids within the past month; 6. Presence of severe cardiovascular cerebrovascular gastrointestinal or hematological diseases; 7. Pregnant or planning to become pregnant or breastfeeding women; 8. Allergic to the study drug or having an allergic constitution.

Design outcomes

Primary

MeasureTime frame
Western Ontario and McMaster Universities Arthritis Index;

Secondary

MeasureTime frame
Inflammatory cytokines;Visual analogue scale;Lequesne index;Quantitative Scoring Standard for Traditional Chinese Medicine Syndromes;

Countries

China

Contacts

Public ContactQiugen Wang

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

wangqiugen@126.com+86 13801862558

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026